In this video, Jennifer A. Woyach, MD, discusses two abstracts from ASH Annual Meeting and Exhibition that evaluated the use of immune therapies to treat chronic lymphocytic leukemia.

Fixed-duration acalabrutinib and venetoclax, with or without obinutuzumab, may improve outcomes over chemoimmunotherapy in patients with previously untreated CLL.

Researchers have found Brukinsa to be a potentially safer alternative for patients with chronic lymphocytic leukemia.

TP53突变不仅深刻影响着慢性淋巴细胞白血病（CLL）的疾病进展轨迹，还直接关联到患者的不良预后，成为评估疾病严重程度与制定个性化治疗策略时不可忽视的重要因素。在备受瞩目的第29届欧洲血液协会年会（EHA ...

In the subgroup with 17p deletion or TP53 mutation, zanubrutinib outperformed others with the most favorable HR (0.52) and the highest SUCRA value of 97%.

Panelists discuss exciting updates on Bruton tyrosine kinase (BTK) inhibitors from the 2024 American Society of Hematology ...

Cells treated with ibrutinib and acalabrutinib each had a unique set of 13 m/z signals, which opens up the possibility of studying these metabolites as biomarkers of therapeutic response.

Acalabrutinib–Venetoclax improves progression-free survival and reduces disease progression in untreated chronic lymphocytic ...

慢性淋巴细胞白血病（CLL）患者中，约10%会经历一种致命转变——转化为侵袭性更强的弥漫大B细胞淋巴瘤（DLBCL），这一过程被称为“Richter转化”（RT-DLBCL）。尽管此类患者的中位生存期不足1年，但关于其生物学特征的研究长期匮乏。202 ...

Galapagos is dropping its junior CD19 CAR-T as part of the Belgian biotech’s seemingly never-ending mission to recalibrate ...

New York–based hematologist-oncologist and clinical researcher works to lower the barriers to enrolling in clinical trials.

The CRISTALLO trial showed that venetoclax plus obinutuzumab achieved high minimal residual disease negativity as a frontline chronic lymphocytic leukemia therapy.